var data={"title":"Glucarpidase: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Glucarpidase: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/391270?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=glucarpidase-drug-information\" class=\"drug drug_general\">see &quot;Glucarpidase: Drug information&quot;</a> and <a href=\"topic.htm?path=glucarpidase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Glucarpidase: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14266243\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Voraxaze</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14315381\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Enzyme</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14315388\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=glucarpidase-drug-information\" class=\"drug drug_general\">see &quot;Glucarpidase: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Methotrexate toxicity:</b> Infants, Children, and Adolescents: IV: 50 units/kg as a single dose (Buchen 2005; Widemann 1997; Widemann 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intrathecal methotrexate overdose:</b> Limited data available: Children &ge;5 years and Adolescents: Intrathecal: 2,000 units as soon as possible after accidental exposure (O&rsquo;Marcaigh 1996; Widemann 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Methotrexate toxicity:</b> IV: 50 units/kg (Buchen 2005; Widemann 1997; Widemann 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants, Children, Adolescents, and Adults: No dosage adjustments necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants, Children, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; has not been studied</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112216\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">Infants, Children, and Adolescents: No dosage adjustments necessary</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112217\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; has not been studied</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8092342\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=glucarpidase-drug-information\" class=\"drug drug_general\">see &quot;Glucarpidase: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Leucovorin calcium is a substrate for glucarpidase and may compete with methotrexate for binding sites; <b>do not administer leucovorin calcium within 2 hours before or after glucarpidase.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Methotrexate toxicity:</b> IV: 50 units/kg as a single dose (Buchen 2005; Widemann 1997; Widemann 2010); may require a second dose 24 hours later (Schwartz 2007; Widemann 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intrathecal methotrexate overdose (off-label route/use):</b> Intrathecal: 2,000 units as soon as possible after accidental methotrexate overdose (Widemann 2004)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50992101\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50989333\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13743258\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Voraxaze: 1000 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13743098\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11233912\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Voraxaze is distributed through ASD Healthcare; procurement information is available (24 hours a day; 365 days a year) at 1-855-7-VORAXAZE (1-855-786-7292). Voraxaze is also commercially available in the U.S. through certain pharmacy wholesalers on a drop-ship basis; orders will only be processed during business hours for overnight delivery. For additional information, refer to http://www.btgplc.com/products/specialty-pharmaceuticals/voraxaze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14315389\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Prior to administration, flush IV line; infuse glucarpidase over 5 minutes; flush IV line after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal: In clinical reports, the 2,000 unit dose was administered over 5 minutes via lumbar route, ventriculostomy, Ommaya reservoir, or lumbar and ventriculostomy (O'Marcaigh 1996; Widemann 2004); other reports of lower doses (1,000 units) have been administered through ventricular or lumbar catheter over 5 minutes (O'Marcaigh 1996)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13743114\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze.  Reconstituted solutions should be used immediately or may be stored for up to 4 hours under refrigeration. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14315382\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of toxic plasma methotrexate concentrations (&gt;1 micromole/L) in patients with delayed clearance due to renal impairment (FDA approved in ages &ge;1 month and adults); has also been used as a rescue agent to reduce methotrexate toxicity in patients with accidental intrathecal methotrexate overdose</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> Due to the risk of subtherapeutic methotrexate exposure, glucarpidase is <b>not</b> indicated when methotrexate clearance is within expected range (plasma methotrexate concentration &le;2 standard deviations of mean methotrexate excretion curve specific for dose administered) <b>or</b> with normal renal function or mild renal impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8092329\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing, hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea/vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Blurred vision, diarrhea, hypersensitivity reaction, hypertension, localized warm feeling, skin rash, throat irritation, tremor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13743103\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8092323\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Serious allergic reactions have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Leucovorin calcium: Leucovorin calcium administration should be continued after glucarpidase; the same dose as was given prior to glucarpidase should be continued for the first 48 hours after glucarpidase; after 48 hours, leucovorin doses should be based on methotrexate concentrations. A single methotrexate concentration should not determine when leucovorin should be discontinued; continue leucovorin until the methotrexate concentration remains below the threshold for leucovorin treatment for &ge;3 days. Leucovorin calcium is a substrate for glucarpidase and may compete with methotrexate for binding sites; <b>do not administer leucovorin calcium within 2 hours before or after glucarpidase.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hydration/alkalinization: In addition to leucovorin, glucarpidase use should be accompanied with adequate hydration and urinary alkalinization.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intrathecal methotrexate overdose: Glucarpidase for intrathecal methotrexate overdose (off-label route/use) should be used in conjunction with immediate lumbar drainage; concurrent dexamethasone (4 mg IV every 6 hours for 4 doses) may minimize methotrexate-induced chemical arachnoiditis; leucovorin calcium (100 mg IV every 6 hours for 4 doses) may prevent systemic methotrexate toxicity (Widemann, 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Monitoring methotrexate: During the first 48 hours after glucarpidase administration, the only reliable method of measuring methotrexate concentrations is the chromatographic method. DAMPA, an inactive methotrexate metabolite with a half-life of 9 hours, may interfere with immunoassay and result in the overestimation of the methotrexate concentration (when collected within 48 hours of glucarpidase administration).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple doses: The utility of more than one glucarpidase dose in reducing plasma methotrexate levels was evaluated in a study of 100 patients with high-dose methotrexate-induced nephrotoxicity (Widemann 2010). Glucarpidase 50 units/kg IV was administered either as a single dose (n=65), 2 doses given 24 hours apart (n=28), or 3 doses given at 4 hour intervals (n=7). Six of the 65 patients randomized to a single dose also received a second delayed glucarpidase dose (&gt;24 hours later) due to persistent methotrexate concentrations &ge;1 micromole/L in spite of a &ge;90% decrease in the plasma methotrexate concentration after the initial dose. The use of scheduled second and third glucarpidase doses did not result in additional methotrexate concentration decreases; and only 2 of the 6 patients who received a second delayed glucarpidase dose (&gt;24 hours later) experienced a &ge;50% methotrexate concentration reduction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25881807\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In children, upon resolution of renal dysfunction following glucarpidase therapy, rechallenge with high-dose methotrexate therapy has been successfully completed; monitor renal function and serum methotrexate concentrations closely in these patients (Christensen 2012). Glucarpidase for intrathecal methotrexate overdose should be used in conjunction with immediate lumbar drainage; in a case series of seven patients including four children (5 to 9 years of age) concurrent dexamethasone (4 mg IV every 6 hours for 4 doses) may minimize methotrexate-induced chemical arachnoiditis; leucovorin calcium (100 mg IV every 6 hours for 4 doses) may prevent systemic methotrexate toxicity (Widemann 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14395087\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14395085\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=86261&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Leucovorin Calcium-Levoleucovorin: Glucarpidase may decrease serum concentrations of the active metabolite(s) of Leucovorin Calcium-Levoleucovorin. Specifically, 6S-5-methyltetrahydrofolateconcentrations may be reduced. Glucarpidase may decrease the serum concentration of Leucovorin Calcium-Levoleucovorin.  Management: Avoid leucovorin administration within 2 hours of glucarpidase dosing.  Continue to administer the pre-glucarpidase leucovorin dose for at least the first 48 hours after glucarpidase administration, and dose based on methotrexate concentration thereafter.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13743100\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13743101\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. If administered to a pregnant woman, the risk to the fetus is unknown; use only if clearly needed. In general, medications used as antidotes should take into consideration the health and prognosis of the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14315390\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum methotrexate concentrations using chromatographic method if &lt;48 hours from glucarpidase administration (DAMPA interferes with immunoassay results until &gt;48 hours). CBC with differential, bilirubin, ALT, AST, serum creatinine; evaluate for signs/symptoms of methotrexate toxicity </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8092335\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Glucarpidase is a recombinant enzyme which rapidly hydrolyzes the carboxyl-terminal glutamate residue from extracellular methotrexate into inactive metabolites (DAMPA and glutamate), resulting in a rapid reduction of methotrexate concentrations independent of renal function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8092337\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Methotrexate toxicity: Reduces methotrexate concentrations by &ge;97% within 15 minutes of IV administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Methotrexate toxicity: Maintains a &gt;95% reduction of methotrexate concentrations for up to 8 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: IV: 3.6 L; distribution restricted to plasma volume</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: Normal renal function: Serum glucarpidase activity levels: 5.6 hours; Serum total glucarpidase: ~9 hours. Impaired renal function (CrCl &lt;30 mL/minute): 8 to 10 hours (Phillips 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51196138\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal function impairment: The pharmacokinetics of glucarpidase in subjects with severe renal impairment (CrCl &lt;30 mL/minute) were similar to those observed in healthy subjects except for a longer half-life of 8.2 hours compared with 5.6 hours in healthy subjects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14790083\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Leucovorin calcium administration should be continued after glucarpidase; the same dose as was given prior to glucarpidase should be continued for the first 48 hours after glucarpidase; after 48 hours, leucovorin doses should be based on methotrexate concentrations. A single methotrexate concentration should not determine when leucovorin should be discontinued; continue leucovorin until the methotrexate concentration remains below the threshold for leucovorin treatment for &ge;3 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322584\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Voraxaze Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (1): $34,456.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25316665\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Voraxaze (SG)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Buchen S, Ngampolo D, Melton RG, et al, &ldquo;Carboxypeptidase G2 Rescue in Patients With Methotrexate Intoxication and Renal Failure,&rdquo; <i>Br J Cancer</i>, 2005, 92(3):480-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucarpidase-pediatric-drug-information/abstract-text/15668713/pubmed\" target=\"_blank\" id=\"15668713\">15668713</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Christensen AM, Pauley JL, Molinelli AR, et al, &ldquo;Resumption of High-Dose Methotrexate After Acute Kidney Injury and Glucarpidase Use in Pediatric Oncology Patients,&rdquo; <i>Cancer</i>, 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucarpidase-pediatric-drug-information/abstract-text/22252903/pubmed\" target=\"_blank\" id=\"22252903\">22252903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Marcaigh AS, Johnson CM, Smithson WA, et al, &quot;Successful Treatment of Intrathecal Methotrexate Overdose by Using Ventriculolumbar Perfusion and Intrathecal Instillation of Carboxypeptidase G2,&quot; <i>Mayo Clin Proc</i>, 1996, 71(2):161-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucarpidase-pediatric-drug-information/abstract-text/8577190/pubmed\" target=\"_blank\" id=\"8577190\">8577190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips M, Smith W, Balan G, et al, &ldquo;Pharmacokinetics of Glucarpidase in Subjects With Normal and Impaired Renal Function,&rdquo; <i>J Clin Pharmacol</i>, 2008, 48(3):279-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucarpidase-pediatric-drug-information/abstract-text/18192538/pubmed\" target=\"_blank\" id=\"18192538\">18192538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Voraxaze (glucarpidase) [prescribing information]. Brentwood, TN: BTG International Inc; March 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Widemann BC, Balis FM, Kim A, et al, &ldquo;Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome,&rdquo; <i>J Clin Oncol</i>, 2010, 28(25):3979-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucarpidase-pediatric-drug-information/abstract-text/20679598/pubmed\" target=\"_blank\" id=\"20679598\">20679598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Widemann BC, Balis FM, Murphy RF, et al, &ldquo;Carboxypeptidase-G2, Thymidine, and Leucovorin Rescue in Cancer Patients With Methotrexate-Induced Renal Dysfunction,&rdquo; <i>J Clin Oncol</i>, 1997, 15(5):2125-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucarpidase-pediatric-drug-information/abstract-text/9164227/pubmed\" target=\"_blank\" id=\"9164227\">9164227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Widemann BC, Balis FM, Shalabi A, et al, &ldquo;Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2,&rdquo; <i>J Natl Cancer Inst</i>, 2004, 96(20):1557-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/glucarpidase-pediatric-drug-information/abstract-text/15494606/pubmed\" target=\"_blank\" id=\"15494606\">15494606</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 86261 Version 53.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F14266243\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F14315381\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F14315388\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51112216\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51112217\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8092342\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50992101\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50989333\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F13743258\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F13743098\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11233912\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14315389\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F13743114\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F14315382\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8092329\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F13743103\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8092323\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25881807\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F14395087\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F14395085\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F13743100\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13743101\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F14315390\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8092335\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8092337\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51196138\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F14790083\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322584\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F25316665\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/86261|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=glucarpidase-drug-information\" class=\"drug drug_general\">Glucarpidase: Drug information</a></li><li><a href=\"topic.htm?path=glucarpidase-patient-drug-information\" class=\"drug drug_patient\">Glucarpidase: Patient drug information</a></li></ul></div></div>","javascript":null}